Keros Therapeutics or Arrowhead Pharmaceuticals: Which Stock Has More Upside?
Arrowhead Pharmaceuticals surged 28% during the past Month. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer Keros Therapeutics gives you more. Keros Therapeutics (KROS) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Arrowhead Pharmaceuticals (ARWR) stock, suggesting you may be better off investing in KROS
- KROS’s Last 12 Months revenue growth was 37798.3%, vs. ARWR’s 23258.2%.
- In addition, its Last 3-Year Average revenue growth came in at 15245.3%, ahead of ARWR’s 7719.5%.
- KROS’s LTM margin is higher: 18.2% vs. ARWR’s 11.9%.
These differences become even clearer when you look at the financials side by side. The table highlights how ARWR’s fundamentals stack up against those of KROS on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| ARWR | KROS | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 94.3 | 18.4 | KROS |
| Revenue Growth | |||
| Last Quarter | � | 3575.8% | KROS |
| Last 12 Months | 23258.2% | 37798.3% | KROS |
| Last 3 Year Average | 7719.5% | 15245.3% | KROS |
| Operating Margins | |||
| Last 12 Months | 11.9% | 18.2% | KROS |
| Last 3 Year Average | -5666.8% | -658009.9% | ARWR |
| Momentum | |||
| Last 3 Year Return | 65.8% | -57.8% | ARWR |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: ARWR Revenue Comparison | KROS Revenue Comparison
See more margin details: ARWR Operating Income Comparison | KROS Operating Income Comparison
- Can AppLovin Stock Recover If Markets Fall?
- With Salesforce Stock Sliding, Have You Assessed The Risk?
- With Southwest Airlines Stock Surging, Have You Considered The Downside?
- Is Walt Disney Stock Built to Withstand More Downside?
- Would You Still Hold VSE Stock If It Fell Another 30%?
- What’s The Downside Risk For XRP?
See detailed fundamentals on Buy or Sell KROS Stock and Buy or Sell ARWR Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| ARWR Return | 21% | -14% | -39% | -25% | -39% | 270% | 10% | ||
| KROS Return | 251% | -17% | -18% | -17% | -60% | 30% | 3% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 113% | <=== | |
| Monthly Win Rates [3] | |||||||||
| ARWR Win Rate | 50% | 50% | 42% | 25% | 42% | 67% | 46% | ||
| KROS Win Rate | 56% | 42% | 50% | 50% | 33% | 50% | 47% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | 65% | <=== | |
| Max Drawdowns [4] | |||||||||
| ARWR Max Drawdown | -68% | -24% | -58% | -48% | -42% | -47% | -48% | ||
| KROS Max Drawdown | 0% | -59% | -56% | -44% | -61% | -40% | -43% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 12/30/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read KROS Dip Buyer Analyses and ARWR Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Still not sure about ARWR or KROS? Consider portfolio approach.
A Multi Asset Portfolio Beats Picking Stocks Alone
Stocks can jump or crash but different assets move on different cycles. A multi asset portfolio helps you stay invested while cushioning swings in equities.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices